MedTrace Logo

Turning Dexmedetomidine Into a Powerful Anesthetic That Can be Rapidly and Completely Reversed

NCT04942340 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2023-05-17

No results posted yet for this study

Summary

In this study, the investigators will explore Atipamezole \& caffeine's ability to facilitate the emergence from anesthesia. Each subject will visit UChicago 4 times. The first time for informed consent. The second time for a complete physical exam to ensure that the subjects are healthy. Then there are 2 sedation sessions. Subjects get an honorarium for each sedation session.

Conditions

  • Emergence From Anesthesia

Interventions

DRUG

Atipamezole & Caffeine

In this arm, subjects will be infused with Atipamezole (2 g/kg) and caffeine (15 mg/kg) across 5 minutes

DRUG

Dexmedetomidine Hydrochloride & Saline

In this arm, subjects will be infused with Precedex \& Saline at 15 mg/kg across 5 minutes

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-31
Primary Completion
2026-04-30
Completion
2026-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04942340 on ClinicalTrials.gov